Clinical presentation and diagnostic evaluation of pheochromocytoma: case series and literature review

References

• Manger WM. 2009. The protean manifestations of pheochromocytoma. Horm Metab Res. 41(9):658–8. doi:10.1055/s-0028-1128139
   PubMed Web of Science ®Google Scholar
• Farrugia FA, Martikos G, Tzanetis P, Charalampopoulos A, Misiakos E, Zavras N, Sotiropoulos D. Pheochromocytoma, diagnosis and treatment: review of the literature. Endocr Regul. 2017;51(3):168–81. doi:10.1515/enr-2017-0018.
   PubMedGoogle Scholar
• Pappachan JM, Raskauskiene D, Sriraman R, Edavalath M, Hanna FW. 2014. Diagnosis and management of pheochromocytoma: a practical guide to clinicians. Curr Hypertens Rep. 16(7):442. doi:10.1007/s11906-014-0442-z
   PubMed Web of Science ®Google Scholar
• Guerrero MA, Schreinemakers JMJ, Vriens MR, Suh, I., Hwang, J., Shen, W. T., & Duh, Q. Y. Clinical spectrum of pheochromocytoma. J Am Coll Surg. 2009;209(6):727–32. doi:10.1016/j.jamcollsurg.2009.09.022.
   PubMed Web of Science ®Google Scholar
• Pamporaki C, Hamplova B, Peitzsch M, Prejbisz, A., Beuschlein, F., Timmers, H. J. & Eisenhofer, G. Characteristics of pediatric vs adult pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2017;102(4):1122–32. doi:10.1210/jc.2016-3829.
   PubMed Web of Science ®Google Scholar
• Lenders JWM, Duh QY, Eisenhofer G, Gimenez-Roqueplo A-P, Grebe SKG, Murad MH, Naruse M, Pacak K, Young WF. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42. doi:10.1210/jc.2014-1498.
   PubMed Web of Science ®Google Scholar
• Arnaldi G, Boscaro M. 2012. Adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab. 26(4):405–19. doi:10.1016/j.beem.2011.12.006
   PubMed Web of Science ®Google Scholar
• Lo CY, Lam KY, Wat MS, Lam KS. 2000. Adrenal pheochromocytoma remains a frequently overlooked diagnosis. Am J Surg. 179(3):212–15. doi:10.1016/s0002-9610(00
   PubMed Web of Science ®Google Scholar
• Amar L, Servais A, A-P G-R, Zinzindohoue F, Chatellier G, Plouin P-F. 2005. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab. 90(4):2110–16. doi:10.1210/jc.2004-1398
   PubMed Web of Science ®Google Scholar
• Mannelli M, Ianni L, Cilotti A, Conti A. 1999. Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol. 141(6):619–24. doi:10.1530/eje.0.1410619
   PubMed Web of Science ®Google Scholar
• Chen H, Sippel RS, O’Dorisio MS, Vinik AI, Lloyd RV, Pacak K. 2010. The North American neuroendocrine tumor society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 39(6):775–83. doi:10.1097/MPA.0b013e3181ebb4f0
   PubMed Web of Science ®Google Scholar
• Lenders JWM, Eisenhofer G, Mannelli M, Pacak PK. Phaeochromocytoma. Lancet. 2005;366(9486):665–75.doi:10.1016/S0140-6736(05)67139-5.
   PubMed Web of Science ®Google Scholar
• Pourian M, Mostafazadeh DB, Soltani A. Does this patient have pheochromocytoma? A systematic review of clinical signs and symptoms. J Diabetes Metab Disord. 2015;15:11. 10.1186/s40200-016-0230-1.
   PubMedGoogle Scholar
• Sheps SG, Jiang NS, Klee GG. Diagnostic evaluation of pheochromocytoma. Endocrinol Metab Clin North Am. 1988;17(2):397–414.doi:10.1016/S0889-8529(18)30426-2.
   PubMed Web of Science ®Google Scholar
• Pacak K, Chrousos GP, Koch CA, Lenders JWM, Eisenhofer G. Pheochromocytoma: Progress in diagnosis, therapy and genetics Adrenal Disorders. In: Margioris AN, Chrousos GP, Eds. 1st Edn. Totowa, NJ, USA: Humana Press.; 2001:379–413.
   Google Scholar
• Pogorzelski R, Toutounchi S, Krajewska E, Fiszer P, Łykowski M, Zapała Ł, Szostek M, Jakuczun W, Pachucki J, Skórski M, et al. The effect of surgical treatment of phaeochromocytoma on concomitant arterial hypertension and diabetes mellitus in a single-centre retrospective study. Cent Eur J Urol. 2014;67(4):361–65. doi:10.5173/ceju.2014.04.art9.
   PubMedGoogle Scholar
• Baguet J-P, Hammer L, Mazzuco TL, Chabre O, Mallion JM, Sturm N, Chaffanjon P. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol. 2004;150(5):681–86. doi:10.1530/eje.0.1500681.
   PubMed Web of Science ®Google Scholar
• Adler JT, Meyer-Rochow GY, Chen H, Benn DE, Robinson BG, Sippel RS, Sidhu SB. Pheochromocytoma: current approaches and future directions. Oncologist. 2008;13(7):779–93. doi:10.1634/theoncologist.2008-0043.
   PubMed Web of Science ®Google Scholar
• La Batide-Alanore A, Chatellier G, Plouin P-F. 2003. Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertens. 21(9):1703–07. doi:10.1097/00004872-200309000-00020
   PubMed Web of Science ®Google Scholar
• Eisenhofer G, Prejbisz A, Peitzsch M, Pamporaki C, Masjkur J, Rogowski-Lehmann N, Langton K, Tsourdi E, Pęczkowska M, Fliedner S, et al. Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated o-methylated catecholamine metabolites. Clin Chem. 2018;64(11):1646–56. doi:10.1373/clinchem.2018.291369.
   PubMed Web of Science ®Google Scholar
• Buffet A, Venisse A, Nau V, Roncellin I, Boccio V, Le Pottier N, Boussion M, Travers C, Simian C, Burnichon N, et al. A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. Horm Metab Res. 2012;44(5):359–66. doi:10.1055/s-0032-1304594.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, Rosei, E. A., & Azizi, M. ESC/ESH Guidelines for the management of arterial hypertension. J Hypertens. 2018;2018(36):1953–2041. doi:10.1093/eurheartj/ehy339.
   Google Scholar
• Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH. von Hippel-Lindau disease. Lancet (London, England). 2003;361(9374):2059–67. doi:10.1016/S0140-6736(03.
   PubMed Web of Science ®Google Scholar
• Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Prim. 2017;3:17004. 10.1038/nrdp.2017.4.
   PubMed Web of Science ®Google Scholar
• Baysal BE, Willett-Brozick JE, Lawrence EC, Drovdlic, C. M., Savul, S. A., McLeod, D. R. & Rubinstein, W. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet. 2002;39(3):178–83. doi:10.1136/jmg.39.3.178.
   PubMed Web of Science ®Google Scholar
• Astuti D, Latif F, Dallol A, Dahia, P. L., Douglas, F., George, E. & Maher, E. R. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet. 2001;69(1):49–54. doi:10.1086/321282.
   PubMed Web of Science ®Google Scholar
• Modigliani E, Vasen HM, Raue K, Dralle, H., Frilling, A., Gheri, R. G. & Euromen Study Group. Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group. J Intern Med. 1995;238(4):363–67. doi:10.1111/j.1365-2796.1995.tb01211.x.
   PubMed Web of Science ®Google Scholar
• Thai E, Gnetti L, Gilli A, Caruana P, Valle R, Buti S. 2015. Very late recurrence of an apparently benign pheochromocytoma. J Can Res Ther. 11(4):1036. doi:10.4103/0973-1482.154942
   PubMed Web of Science ®Google Scholar
• Manu P, Runge LA. 1984. Biochemical screening for pheochromocytoma. Superiority of urinary metanephrines measurements. Am J Epidemiol. 120(5):788–90. doi:10.1093/oxfordjournals.aje.a113947
   PubMed Web of Science ®Google Scholar
• Perry CG, Sawka AM, Singh R, Thabane L, Bajnarek J, Young WFJ. 2007. The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma. Clin Endocrinol (Oxf). 66(5):703–08. doi:10.1111/j.1365-2265.2007.02805.x
   PubMed Web of Science ®Google Scholar
• Jalil ND, Pattou FN, Combemale F, Chapuis Y, Henry J-F, Peix J-L, Proye CAG. Effectiveness and limits of preoperative imaging studies for the localisation of pheochromocytomas and paragangliomas: a review of 282 cases. French association of surgery (AFC), and the French association of endocrine surgeons (AFCE). Eur J Surg. 2003;164(1):23–28. doi:10.1080/110241598750004913.
   Google Scholar
• Lumachi F, Tregnaghi A, Zucchetta P, Cristina Marzola M, Cecchin D, Grassetto G, Bui F. Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study. Nucl Med Commun. 2006;27(7):583–87. doi:10.1097/00006231-200607000-00006.
   PubMed Web of Science ®Google Scholar
• Luster M, Karges W, Zeich K, Pauls, S., Verburg, F. A., Dralle, H. & Mottaghy, F. M. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. Eur J Nucl Med Mol Imaging. 2010;37(3):484–93. doi:10.1007/s00259-009-1294-7.
   PubMed Web of Science ®Google Scholar
• Berglund AS, Hulthén UL, Manhem P, Thorsson O, Wollmer P, Törnquist C. 2001. Metaiodobenzylguanidine (MIBG) scintigraphy and computed tomography (CT) in clinical practice. Primary and secondary evaluation for localization of phaeochromocytomas. J Intern Med. 249(3):247–51. doi:10.1046/j.1365-2796.2001.00792.x
   PubMed Web of Science ®Google Scholar
• Douma S, Kamparoudis A, Petidis K, Anyfanti P, Doumas M, Gkaliagkousi E, Triantafyllou A, Gavriilaki E, Gerasimidis T, Zamboulis C, et al. Leiomyosarcoma of renal vein, initially resembling pheochromocytoma. Clin Exp Hypertens. 2012;34(6):6. doi:10.3109/10641963.2012.665543.
   Web of Science ®Google Scholar
• Bhatia KSS, Ismail MM, Sahdev A, Rockall AG, Hogarth K, Canizales A, Avril N, Monson JP, Grossman AB, Reznek RH, et al. 123 I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf). 2008;69(2):181–88. doi:10.1111/j.1365-2265.2008.03256.x.
   PubMed Web of Science ®Google Scholar
• Wiseman GA, Pacak K, O’Dorisio MS, Neumann DR, Waxman AD, Mankoff DA, Heiba SI, Serafini AN, Tumeh SS, Khutoryansky N, et al. Usefulness of 123 I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med. 2009;50(9):1448–54. doi:10.2967/jnumed.108.058701.
   PubMed Web of Science ®Google Scholar
• Fiebrich H-B, Brouwers AH, Kerstens MN, Pijl MEJ, Kema IP, de Jong JR, Jager PL, Elsinga PH, Dierckx RAJO, van der Wal JE, et al. 6-[F-18]Fluoro- l -Dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with 123I-Metaiodobenzylguanidine Scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine Excess. J Clin Endocrinol Metab. 2009;94(10):3922–30. doi:10.1210/jc.2009-1054.
   PubMed Web of Science ®Google Scholar
• Amar L, Lussey-Lepoutre C, Lenders J, Djadi-Prat J, Plouin P, Steichen O. 2016. Management of endocrine disease recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and. Eur J Endocrinol. 175(4):R135–145. doi:10.1530/EJE-16-0189
   PubMed Web of Science ®Google Scholar
• Lenders JWM, Eisenhofer G. 2017. Update on modern management of pheochromocytoma and paraganglioma. Endocrinol Metab. 32(2):152–61. doi:10.3803/EnM.2017.32.2.152
   Google Scholar